Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities.
Victoria L Walker, Anna Meyer, Deborah Paauw and 1 others
PMID 34890559WHAT IT FOUND
87 residents in 12 care facilities received on-site bamlanivimab or casirivimab/imdevimab infusions in the first 6 weeks.
The median time from positive test to infusion was 3 days. This does not show the treatment prevented hospitalization or death.
Key findings
01During the initial 6 weeks, 87 residents in 12 post-acute and long-term care sites received on-site infusion of bamlanivimab or casirivimab/imdevimab for early COVID-19.
02The median time to infusion after a positive test result was 3 days.
03The study cannot show whether the infusions affected hospitalization or death.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The registry was not originally designed to evaluate access to treatment in post-acute and long-term care. The registry did not include all positive cases, residents who were positive but ineligible, or outcomes of untreated residents. Data were not structured to identify the percentage of eligible residents with COVID-19. Inconsistent medication order entry likely resulted in some treated residents not being included in the registry. The health system dashboard did not include nonaffiliated sites, limiting its usefulness. Administration in post-acute and long-term care is not publicly reported, so the degree of impact on access cannot be quantified. Conclusions about the impact of treatment on hospitalization and death are not possible from these data.
Declared interests
The supplied text does not report who funded the study or any conflict-of-interest declarations.
The easy way to misread this
Do not read the timely delivery of infusions as proof that bamlanivimab or casirivimab/imdevimab prevented hospitalization or death. The registry did not include all positive cases, ineligible residents, or untreated outcomes, and the authors state that conclusions about impact on hospitalization and death are not possible.